TELA Bio, Inc. (TELA)

Market Cap	112.26M
Revenue (ttm)	68.65M
Net Income (ttm)	-41.52M
Shares Out	39.39M
EPS (ttm)	-1.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	769,460
Open	2.800
Previous Close	2.800
Day's Range	2.710 - 2.960
52-Week Range	2.300 - 7.840
Beta	1.00
Analysts	Strong Buy
Price Target	9.25 (+224.56%)
Earnings Date	Nov 7, 2024

About TELA

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Nov 8, 2019
• Employees: 227
• Stock Exchange: NASDAQ
• Ticker Symbol: TELA
• Website: https://www.telabio.com

Financial Performance

In 2023, TELA Bio's revenue was $58.45 million, an increase of 41.13% compared to the previous year's $41.42 million. Losses were -$46.66 million, 5.35% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for TELA stock is "Strong Buy." The 12-month stock price forecast is $9.25, which is an increase of 224.56% from the latest price.

Price Target

$9.25

(224.56% upside)

Analyst Consensus: Strong Buy